AstraZeneca forms biologics JV in China

AstraZeneca and CSPC Pharmaceutical have moved beyond licensing deals and into shared manufacturing in China. On August 5, CSPC disclosed that the companies signed a joint venture contract to build and operate a next-generation biologics manufacturing facility in Shijiazhuang, the Hebei city where CSPC is based. (www1.hkexnews.hk) The equity split is 51% for CSPC and 49% for AstraZeneca, according to CSPC’s filing. The venture’s initial scope is the manufacturing and supply of mutually agreed biologics drug substances for global markets. The agreement adds a production layer to a relationship that AstraZeneca and CSPC had already been expanding through research and licensing. AstraZeneca said in February it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development in the country. (www1.hkexnews.hk) AstraZeneca also announced a strategic collaboration with CSPC in January 2025 and a separate obesity and type 2 diabetes collaboration in January 2026. ### Why is this more than another China licensing deal? CSPC’s August 5 filing said the joint venture will focus first on biologics drug-substance manufacturing rather than discovery alone. That makes the deal different from the run of China partnerships centered on licensing molecules into multinational pipelines. (www1.hkexnews.hk) PharmExec reported that the venture is designed to combine CSPC’s AI-driven Good Manufacturing Practice system and plant construction and operating capabilities with AstraZeneca’s global quality standards and supply-chain management. Fierce Pharma separately reported that CSPC will contribute the majority of the capital and lead operations through its 51% stake. (astrazeneca.com) ### What exactly will the new company do? The HKEX filing said the joint venture will manufacture and supply biologics drug substances that the two companies mutually agree to include. Drug substance refers to the active biological ingredient made upstream before later fill-finish and packaging steps. (www1.hkexnews.hk) CSPC said the business scope can be expanded later to include more products. The filing also said the partners will jointly manage construction and day-to-day operations by drawing on their respective expertise. ### Why Shijiazhuang? Shijiazhuang is CSPC’s home base, and the city has become the center of several AstraZeneca-CSPC transactions. (pharmexec.com) AstraZeneca’s January 2025 statement on its strategic collaboration with CSPC identified the partner as Shijiazhuang City-based. China Daily reported on August 5 that the plant will be built in Shijiazhuang as a next-generation biologics manufacturing base. (www1.hkexnews.hk) CSPC’s exchange filing did not disclose a capital amount or construction timetable in the excerpt available through HKEX search results. ### How does this fit AstraZeneca’s broader China push? (www1.hkexnews.hk) AstraZeneca said in February that it planned to invest $15 billion in China through 2030 to expand medicines manufacturing and R&D. The company said that investment would use China’s scientific and manufacturing base to supply patients in China and globally. (astrazeneca.com) The CSPC joint venture now gives that strategy a named local manufacturing vehicle in biologics. It also extends a partnership that already included discovery and development agreements across chronic disease, obesity and type 2 diabetes. (chinadaily.com.cn) ### What should readers watch next? CSPC’s August 5 filing is the key document for the next steps because it sets the ownership split, operating structure and initial manufacturing scope. AstraZeneca’s investor-relations events page and media center are the most likely places for any later disclosure on plant timing, capacity or product assignments. (www1.hkexnews.hk) (astrazeneca.com 1) (astrazeneca.com 2)